André Henrique Barbosa de Carvalho

André Henrique Barbosa de Carvalho

Auto-generated profile, based on publicly available information

André Henrique Barbosa de Carvalho

Research and Development Department, Hermes Pardini, Fleury Group, Vespasiano, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2024 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
FMFilipe Moreira
Filipe Moreira
JDJoão Victor Rodrigues Dutra
João Victor Rodrigues Dutra
ACAndré Henrique Barbosa de Carvalho
André Henrique Barbosa de Carvalho
CRClarisse Rezende Reis
Clarisse Rezende Reis
JRJéssica Silqueira Hickson Rios
Jéssica Silqueira Hickson Rios
RARenato Aguiar
Renato Aguiar

28 June 2022 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
MCMaria Raquel Santos Carvalho
Maria Raquel Santos Carvalho
ACAndré Henrique Barbosa de Carvalho
André Henrique Barbosa de Carvalho
GPGiulia Moreira Paiva
Giulia Moreira Paiva
CJCarolina de Castro Andrade Jorge
Carolina de Castro Andrade Jorge
FSFernanda Caroline Dos Santos
Fernanda Caroline Dos Santos
VHVitor Geraldi Haase
Vitor Geraldi Haase

1 January 2026 in JCO Global Oncology
Verified
Journal Article
Closed access
FMFabiana Kalina Marques
Fabiana Kalina Marques
ACAndré Henrique Barbosa de Carvalho
André Henrique Barbosa de Carvalho
VLVLADMIR Cláudio CORDEIRO DE LIMA
VLADMIR Cláudio CORDEIRO DE LIMA
JRJacqueline Siqueira Roberto
Jacqueline Siqueira Roberto
MFMaira Cristina Menezes Freire
Maira Cristina Menezes Freire
PURPOSE: We studied the prevalence of somatic mutations in EGFR, KRAS, BRAF, and NRAS among Brazilian patients with early-stage non–small cell lung cancer (NSCLC). We also explored the association between these mutations and clinicopathologic characteristics. METHODS: We screened 557 patients diagnosed with NSCLC who underwent EGFR , KRAS , BRAF , and NRAS gene sequencing by next-generation sequencing (NGS) or RT-PCR ( EGFR only) between 2021 and 2023. We analyzed the frequency of mutations in these genes and their association with clinical characteristics among 399 patients with early-stage nonsquamous NSCLC. RESULTS: Among 399 patients with early-stage nonsquamous NSCLC included in the analysis, we identified mutations in 218 (54.6%), totaling 224. The median age was 67 years, and most were female (58.9%). The most frequently mutated genes were EGFR and KRAS . Actionable genomic alterations were found in 137 cases, representing 34.3% of the entire cohort and 62.8% of patients with mutations. In cases with actionable mutations identified by NGS, EGFR mutations accounted for 68.0%, followed by KRAS (27.3%) and BRAF (4.7%). We found a significant association between histologic subtype and grade, as well as between tumor T stage and histologic subtype. A higher frequency of EGFR mutations was observed among females. We noted an association between mutated EGFR and the lepidic subtype, mutated KRAS and the mucinous/colloid subtype, and between the nonmutated genotype and the solid/micropapillary subtype. CONCLUSION: This study provides an overview of the genomic landscape of early-stage nonsquamous NSCLC in Brazilian patients. The high prevalence of mutations observed in our cohort underscores the importance of genomic testing in this setting, enabling selection of patients suitable for targeted approved therapies or clinical trials.

1 June 2022 in Dementia & Neuropsychologia
Verified
Journal Article
Open access
ESEmanuelle de Oliveira Silva
Emanuelle de Oliveira Silva
ACAndré Henrique Barbosa de Carvalho
André Henrique Barbosa de Carvalho
GPGiulia Moreira Paiva
Giulia Moreira Paiva
CJCarolina Andrade Jorge
Carolina Andrade Jorge
GKGabriella Koltermann
Gabriella Koltermann
MCMaria Raquel Santos Carvalho
Maria Raquel Santos Carvalho
Monoamine oxidase A (MAOA) polymorphisms have been associated with antisocial disorders. Less attention has been paid to the cognitive functioning of individuals with different MAOA alleles. No study has described the cognitive phenotype associated with the less frequent, low enzyme activity allele, MAOA_LPR*2R. Objective: We describe the cognitive correlates of boys having MAOA_LPR*2R allele, ascertained in a sample of school children with normal intelligence, not referred for behavioral disorders. Methods: Participants were eight boys, attending from the second to fifth grades in state-run schools. They were identified among 712 children with typical general cognitive ability, genotyped for MAOA_LPR polymorphism. Participants were assessed with general intelligence, mathematics and spelling achievement, and verbal and visuospatial working memory tests. Neuropsychological performance was compared to published standards, using 1 SD below the mean as a cutoff value for low performance. Results: Intelligence of boys with MAOA_LPR*2R allele varied from above average (N=2) to low average in the other children. Five out of eight boys with the MAOA_LPR*2R allele had low mathematics achievement, and three presented additional difficulties with spelling. Four out of eight children had low short-term and working memory performance. Discussion: This is the first study describing cognitive correlates and school performance in boys having the MAOA_LPR*2R allele. Having this allele, and therefore, probably low MAO-A activity, does not necessarily imply low intelligence or low school performance. However, learning difficulties, particularly in math, and low working memory performance were observed in boys having this allele. This suggests a role of MAOA in learning difficulties.